Annexon (ANNX) Osake Kurssi

Annexon Inc is primarily active in the biotechnology industry.

The main competitors of Annexon Inc in the market include companies like Biogen Inc, Eli Lilly and Company, and Roche Holding AG.

Annexon Inc is a biopharmaceutical company specializing in developing novel therapies for autoimmune and neurodegenerative diseases. Established in 2011, Annexon has focused on the research and development of therapies that modulate the complement system, aiming to bring transformative treatments to patients. With a team of experienced scientists and researchers, Annexon has successfully advanced their platform technology to tackle a wide range of diseases. Annexon Inc has made significant strides in understanding the complex mechanisms of complement biology, positioning themselves at the forefront of innovative therapeutic approaches. Through strategic collaborations, Annexon Inc continues to drive advancements in the field, offering new hope for patients worldwide.

Annexon Inc, a leading biopharmaceutical company, has achieved several significant milestones. Firstly, the company successfully completed a Series A financing round, raising $34 million in funds. This substantial capital injection allowed Annexon Inc to advance its pioneering research programs. Additionally, Annexon Inc entered into a strategic collaboration with a renowned global pharmaceutical company, which further validates the company's innovative approach. Furthermore, the company's lead product candidate, ANX005, has shown promising results in preclinical studies, positioning Annexon Inc as a frontrunner in the development of novel therapies for autoimmune and neurodegenerative disorders. The continuous achievements of Annexon Inc highlight its dedication to improving patients' lives and further establishing its presence in the biotech industry.

Annexon Inc is primarily present in the United States, with its headquarters located in South San Francisco, California. This biopharmaceutical company focuses on developing therapeutic treatments for patients with autoimmune and neurodegenerative disorders. Annexon's research and development efforts primarily take place in the United States, where they collaborate with leading institutions and professionals in the medical field. The company's primary focus is on advancing its innovative pipeline of therapies to address unmet medical needs in the United States and potentially expand globally in the future.

Annexon Inc represents a strong focus on scientific innovation and excellence in the biopharmaceutical industry. With a commitment to developing transformative therapies for patients with complement-mediated disorders, Annexon Inc prioritizes cutting-edge research and development. The company's corporate philosophy revolves around pushing the boundaries of medical advancements and addressing unmet medical needs. Annexon Inc strives to provide novel treatments that have the potential to significantly improve patients' lives. By combining deep scientific expertise and a passion for breakthrough solutions, Annexon Inc is dedicated to making a positive impact in the field of biotechnology and delivering value to its stakeholders.

Analyytikot asettavat tällä hetkellä Annexon-osakkeelle keskimääräisen tavoitehinnan 10,50 USD (mediaani: 10,50 USD), mikä merkitsee +157,7 % viimeisimpään hintaan verrattuna. Konsensus perustuu 17 analyytikkoarvioon.

Annexon Analyytikkojen kursstavoitteet 2026

17 analyytikkoa arvioi tällä hetkellä Annexon-osaketta: 14 suosittaa ostoa, 3 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Annexon-yhtiöltä 2,36 M USD liikevaihtoa ja −0,98 USD osakekohtaista tulosta.

Annexon Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Annexon-osake noteerataan hintaan 3,64 EUR (4,07 USD).

Annexon-osake (ANNX) on listattuna 1 pörssissä, muun muassa: NASDAQ (ANNX).

Annexon Inc is a biopharmaceutical company based in South San Francisco, California. The company specializes in the development of therapeutics that modulate the complex and sophisticated complement system. These innovative treatment methods aim to effectively treat patients suffering from severe diseases caused by complement system activation. The complement modulation by Annexon is applicable to many serious diseases, many of which currently lack sufficient medical solutions. Examples include autoimmune diseases, inflammatory diseases, or neurodegenerative disorders such as Alzheimer's and Parkinson's. Annexon has conducted careful drug development to successfully place their products in the market. Therefore, their business model includes three main areas. Research and Development: Annexon has built a team of highly qualified experts working together to develop new therapeutics. The research focuses on the development of innovative drugs that modulate the complement system. Currently, three products stand out: ANX005, ANX007, and ANX009. These products have already been deemed safe and effective in clinical trials and cover therapeutic areas such as autoimmune, neurodegenerative, and inflammatory diseases. Collaborations: Annexon actively collaborates with other companies to share ideas and technologies with external partners and create synergies. This involves expanding their research field, generating ideas, and developing solutions. Alongside pharmaceuticals, Annexon has additional molecules in the pipeline that have the potential to serve multiple therapeutic indications. Marketing and Sales: Annexon adopts a flexible yet aggressive approach to market and distribute their products, expanding their market position and promoting the acceptance of complement modulators as a new therapy. So far, the company has relied on service organizations and treatment centers. Annexon will also engage in discussions with the regulatory authority (FDA) to explore ways to expedite the approval processes for complement modulators. Overall, Annexon has a successful strategy based on the research and development of innovative therapies, as well as the marketing and sales of their products. Their business model is designed to meet the needs of patients, physicians, and investors by focusing on the development of effective therapeutics to have a positive impact on serious diseases such as autoimmune diseases or neurodegenerative disorders. The company relies on innovative solutions and collaboration with other companies to proactively advance the development of innovative drugs.

odotettu liikevaihto Annexon on 2,36 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Annexon on −151,78 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Annexon:n hinta-voitto-suhde (P/E) on tällä hetkellä −4,16. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Annexon-osakkeen arvostusta.

Annexon:n hinta-myynti-suhde (P/S) on tällä hetkellä 267,54. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Annexon-osakkeen arvostuskennuslukuna.

Annexon:n Eulpool-laatuscore on 2/10.

Annexon:n ISIN on US03589W1027. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Annexon:n WKN on A2P859. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Annexon:n ticker on ANNX. Tämä pörssinoteeraus käytetään Annexon-osakkeiden kauppaan pörssissä.